Dehydrosoyasaponin I

Dehydrosoyasaponin I at a Glance

Dehydrosoyasaponin I (DHS-I) is a triterpene saponin from Desmodium adscendens, the West African herb used traditionally for asthma.

It has a genuine place in pharmacology history: it was the first high-affinity opener of the BK (maxi-K) potassium channel ever found — Ki 120 nM, active at 10 nM, and dependent on the smooth-muscle beta-1 subunit. Before DHS-I there was no potent pharmacological tool for opening that channel.

Opening BK channels hyperpolarises smooth muscle and relaxes it, which is a coherent mechanism for the plant’s traditional airway use — and the compound remains primarily a research tool rather than a therapeutic candidate.

What It's Used For

Dehydrosoyasaponin I is one of the most interesting molecules here and almost certainly not a medicine. In 1993 a Merck group screening a Ghanaian anti-asthma herb — Desmodium adscendens, taken as a decoction for asthma — isolated three triterpene saponins and found that one of them, DHS-I, was the first high-affinity activator of calcium-dependent potassium channels ever described ^{1Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →}.

That is a genuinely rare event in herbal pharmacology: a traditional respiratory remedy resolving to a named molecule acting on a named ion channel, in the tissue the tradition points at. The literature that followed characterised the mechanism in unusual depth ^{2,3Reference 2Giangiacomo et al. · 1998In vitroMechanism of maxi-K channel activation by dehydrosoyasaponin-I — in vitroView study →Reference 3McManus et al. · 1995In vitroFunctional role of the beta subunit of high conductance calcium-activated potassium channels — in vitroView study →} — and then stopped, because the same work established why the molecule cannot do in a person what it does in a lipid bilayer. DHS-I acts only from the intracellular face of the channel ^{2Reference 2Giangiacomo et al. · 1998In vitroMechanism of maxi-K channel activation by dehydrosoyasaponin-I — in vitroView study →}, and it is a large, sugar-bearing saponin from a class with 0.5–2.9% intestinal transfer that human subjects excrete unabsorbed ^{7Reference 7Hu et al. · 2004Clinical trialSoyasaponin I and sapogenol B have limited absorption by Caco-2 intestinal cells and limited bioavailability in women — human study and in vitroView study →}.

Everything below is in vitro. Read it as a mechanism story and a tool-compound story, not as a reason to drink the tea.

Mechanisms

Pharmacokinetics

No pharmacokinetic study of DHS-I exists, and the reason to state that up front is that two independent facts make oral activity close to impossible — which is the most decision-relevant thing here.

First, the site of action is inside the cell. DHS-I activates the channel from the intracellular side of the membrane ^{1,2Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →Reference 2Giangiacomo et al. · 1998In vitroMechanism of maxi-K channel activation by dehydrosoyasaponin-I — in vitroView study →}; in the defining experiments it was applied to the cytoplasmic face of an excised patch or a reconstituted bilayer. A large polar glycoside does not cross a plasma membrane readily, so even a molecule delivered perfectly to the airway would still be on the wrong side of it.

Second, its class is barely absorbed. In the only human study located, eight women ingested 434 µmol of group B soyasaponins; neither the saponins nor their metabolites appeared in 24-hour urine, and 36.3 ± 10.2 µmol of the aglycone soyasapogenol B was recovered from a 5-day faecal collection ^{7Reference 7Hu et al. · 2004Clinical trialSoyasaponin I and sapogenol B have limited absorption by Caco-2 intestinal cells and limited bioavailability in women — human study and in vitroView study →}. In the matched Caco-2 work, mucosal transfer of soyasaponin I was 0.5–2.9% ^{7Reference 7Hu et al. · 2004Clinical trialSoyasaponin I and sapogenol B have limited absorption by Caco-2 intestinal cells and limited bioavailability in women — human study and in vitroView study →}. Soyasaponins are poorly absorbed in the small intestine and are instead deglycosylated by colonic bacteria to their aglycones. DHS-I itself was not measured in that study — it is a 22-oxo (soyasapogenol E) saponin rather than a group B one — so this is an inference across a closely related family, and it is stated as such. But it points hard in one direction: the molecule would have to survive the gut, be absorbed against a 1–3% ceiling, escape microbial deglycosylation, distribute to airway smooth muscle, and then cross into the cytoplasm.

That chain is why DHS-I’s thirty-year career has been as a research tool — the reagent you use to open a BK channel in a bilayer — rather than as a drug candidate or a rationale for a herbal product.

Clinical trials

No registered clinical trials of dehydrosoyasaponin I were identified, and no human study of the isolated compound exists. The evidence base is in-vitro electrophysiology and binding work.

Last checked: August 2026.

Isolate vs. Plant Studies

The split here is unusually clean and unusually awkward. Every result about DHS-I used the purified molecule at an isolated membrane — no extract, no cell, no animal ^{1,2,3Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →Reference 2Giangiacomo et al. · 1998In vitroMechanism of maxi-K channel activation by dehydrosoyasaponin-I — in vitroView study →Reference 3McManus et al. · 1995In vitroFunctional role of the beta subunit of high conductance calcium-activated potassium channels — in vitroView study →}. Every result about D. adscendens used the extract in guinea pigs or rats and named no constituent ^{5,6Reference 5Addy et al. · 1984AnimalEffects of the extracts of Desmodium adscendens on anaphylaxis — animal model (guinea pig)View study →Reference 6Quaye et al. · 2017AnimalAcute and subchronic toxicity studies of aqueous extract of Desmodium adscendens (Sw) DC — animal model (rat)View study →}. The two literatures were produced by different people for different reasons and have never been joined.

So the familiar claim — “Desmodium works for asthma because it contains a BK-channel opener” — is an inference stacked on two unbridged bodies of work. Both halves are real. The bridge is not there, and the pharmacokinetics ^{7Reference 7Hu et al. · 2004Clinical trialSoyasaponin I and sapogenol B have limited absorption by Caco-2 intestinal cells and limited bioavailability in women — human study and in vitroView study →} suggest it may not be buildable by the oral route.

One further discipline applies to this whole page: Desmodium is a genus, not a plant. The BK-channel work belongs specifically to D. adscendens, the West African anti-asthma species. It does not read across to D. gangeticum, the Ayurvedic Salaparni marked by gangetin, whose cardioprotective and antiulcer literature is entirely separate ^{9Reference 9Rastogi et al. · 2011ReviewAn ethnomedicinal, phytochemical and pharmacological profile of Desmodium gangeticum (L.) DC. and Desmodium adscendens (Sw.) DC — reviewView study →}.

Prevalence in Nature

Dehydrosoyasaponin I is an oleanane-type triterpenoid saponin — a pentacyclic triterpene aglycone carrying a sugar chain at C-3. Structurally it is the 22-oxo analogue of soyasaponin I: same trisaccharide, but the C-22 hydroxyl of soyasapogenol B is oxidised to a ketone, giving the soyasapogenol E aglycone. That single carbonyl is what separates a pharmacologically remarkable molecule from an ordinary legume saponin, in both the channel work ^{1Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →} and the insect work ^{8Reference 8Taylor et al. · 2004In vitroInsecticidal components from field pea extracts — soyasaponins and lysolecithins — in vitro bioassayView study →}.

Its occurrence is a legume (Fabaceae) story. It was isolated from tick trefoil (Desmodium adscendens) ^{1Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →} and is reported as a minor component of field pea (Pisum sativum) and soybean (Glycine max), while being absent from chickpea ^{8Reference 8Taylor et al. · 2004In vitroInsecticidal components from field pea extracts — soyasaponins and lysolecithins — in vitro bioassayView study →}. Soyasaponins generally are widespread across the family — soybean, pea, lupin, liquorice relatives — and function as constitutive chemical defences; the antifeedant result ^{8Reference 8Taylor et al. · 2004In vitroInsecticidal components from field pea extracts — soyasaponins and lysolecithins — in vitro bioassayView study →} fits that role. Biosynthetically these come from the mevalonate/oleanane route via β-amyrin, followed by oxidation and glycosylation, with the C-22 oxidation state distinguishing the soyasapogenol B and E series.

Abundance is not quantified. No mg/g or %-dry-weight figure for DHS-I was located in Desmodium, pea or soy. Every source that mentions its level calls it minor, and a patent exists specifically for producing plant compositions enriched in DHS-I — which is itself evidence that the natural concentration is inconveniently low.

Discovery & Synthesis

First isolation, 1993, and the circumstances are worth the detail. A team spanning Merck Research Laboratories and academic collaborators — including M. E. Addy, the Ghanaian researcher whose earlier work had documented the plant’s anti-anaphylactic activity ^{5Reference 5Addy et al. · 1984AnimalEffects of the extracts of Desmodium adscendens on anaphylaxis — animal model (guinea pig)View study →} — went after D. adscendens precisely because it was “a medicinal herb used in Ghana as a treatment for asthma” ^{1Reference 1McManus et al. · 1993In vitroAn activator of calcium-dependent potassium channels isolated from a medicinal herb — in vitroView study →}. They screened for displacement of charybdotoxin from bovine tracheal smooth-muscle membranes, isolated three triterpene glycosides, and found DHS-I to be the first high-affinity opener of calcium-dependent potassium channels reported. The name is descriptive: the dehydro prefix marks it as the oxidised form of soyasaponin I.

No total synthesis of note was located, which is unsurprising — a glycosylated pentacyclic triterpene is a hard target and the demand is a few milligrams of research reagent, not tonnes. It is supplied commercially as an assay reagent, and the practical production route is extraction; a patent covers methods for producing plant compositions enriched in DHS-I, reflecting how little of it the plants make.

Patents: not yet researched (future patent-loop pass).

Dosage

No human dose exists, and none is plausible by mouth. DHS-I has never been administered to a person or to a whole animal. Every figure below is a bath concentration at an isolated membrane or a bioassay endpoint.

These are concentrations used in research and are not a personal recommendation. For the herb itself, dosing is discussed on the tick trefoil page.

Scope Disclosure

• Interactions assessed? Not for this molecule. The documented signal — hepatic CYP induction — belongs to the whole aqueous extract of D. adscendens in rats ^{6Reference 6Quaye et al. · 2017AnimalAcute and subchronic toxicity studies of aqueous extract of Desmodium adscendens (Sw) DC — animal model (rat)View study →}, not to DHS-I.
• Pregnancy/lactation assessed? No. No reproductive or developmental data for isolated DHS-I were located. Guidance for the source herb lives on the tick trefoil page, where intake is actually decided.